Literature DB >> 19727140

Delivering multiple gene products in the brain from a single adeno-associated virus vector.

S B Foti1, R J Samulski, T J McCown.   

Abstract

For certain gene therapy applications, the simultaneous delivery of multiple genes would allow for novel therapies. In the case of adeno-associated virus (AAV) vectors, the limited packaging capacity greatly restricts current methods of carrying multiple transgene cassettes. To address this issue, a recombinant AAV (rAAV) vector was designed such that a furin proteolytic cleavage site (RKRRKR) was placed between the coding sequences of two genes (green fluorescent protein (GFP) and galanin), to allow cleavage of the chimeric protein into two fragments. In addition, these constructs contained the fibronectin secretory signal sequence that causes the gene products to be constitutively secreted from transduced cells. In vitro studies show that after transfection of HEK293 cells, the appropriate cleavage and constitutive secretion occurred regardless of the order of the genes in the transgene cassette. In vivo, infusion of rAAV vectors into the piriform cortex resulted in both GFP expression and significant galanin attenuation of kainic acid-induced seizure activity. Thus, the present results establish the utility of a proteolytic approach for the expression and secretion of multiple gene products from a single AAV vector transgene cassette.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19727140      PMCID: PMC2786958          DOI: 10.1038/gt.2009.106

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  20 in total

Review 1.  Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides.

Authors:  N G Seidah; M Chrétien
Journal:  Brain Res       Date:  1999-11-27       Impact factor: 3.252

2.  Expression of green fluorescent protein as a marker for effects of antileishmanial compounds in vitro.

Authors:  S W Kamau; F Grimm; A B Hehl
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

3.  IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector.

Authors:  H Mizuguchi; Z Xu; A Ishii-Watabe; E Uchida; T Hayakawa
Journal:  Mol Ther       Date:  2000-04       Impact factor: 11.454

4.  Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity.

Authors:  Joseph E Rabinowitz; Fabienne Rolling; Chengwen Li; Hervè Conrath; Weidong Xiao; Xiao Xiao; R Jude Samulski
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

5.  Limitations on the use of fused green fluorescent protein to investigate structure-function relationships for the cauliflower mosaic virus movement protein.

Authors:  C L Thomas; A J Maule
Journal:  J Gen Virol       Date:  2000-07       Impact factor: 3.891

6.  Modification of seizure activity by electrical stimulation. II. Motor seizure.

Authors:  R J Racine
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1972-03

7.  Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease.

Authors:  Y Shen; S I Muramatsu; K Ikeguchi; K I Fujimoto; D S Fan; M Ogawa; H Mizukami; M Urabe; A Kume; I Nagatsu; F Urano; T Suzuki; H Ichinose; T Nagatsu; J Monahan; I Nakano; K Ozawa
Journal:  Hum Gene Ther       Date:  2000-07-20       Impact factor: 5.695

8.  Fusagene vectors: a novel strategy for the expression of multiple genes from a single cistron.

Authors:  J Gäken; J Jiang; K Daniel; E van Berkel; C Hughes; M Kuiper; D Darling; M Tavassoli; J Galea-Lauri; K Ford; M Kemeny; S Russell; F Farzaneh
Journal:  Gene Ther       Date:  2000-12       Impact factor: 5.250

9.  Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion.

Authors:  Rebecca P Haberman; R Jude Samulski; Thomas J McCown
Journal:  Nat Med       Date:  2003-07-13       Impact factor: 53.440

10.  Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII.

Authors:  Paris Margaritis; Valder R Arruda; Majed Aljamali; Rodney M Camire; Alexander Schlachterman; Katherine A High
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

View more
  5 in total

1.  Pronounced Therapeutic Benefit of a Single Bidirectional AAV Vector Administered Systemically in Sandhoff Mice.

Authors:  Hannah G Lahey; Chelsea J Webber; Diane Golebiowski; Cassandra M Izzo; Erin Horn; Toloo Taghian; Paola Rodriguez; Ana Rita Batista; Lauren E Ellis; Misako Hwang; Douglas R Martin; Heather Gray-Edwards; Miguel Sena-Esteves
Journal:  Mol Ther       Date:  2020-06-19       Impact factor: 11.454

2.  Neuropeptide delivery to the brain: a von Willebrand factor signal peptide to direct neuropeptide secretion.

Authors:  Marijke W A de Backer; Maike A D Brans; Mieneke C M Luijendijk; Keith M Garner; Dianne M A van den Heuvel; R Jeroen Pasterkamp; Roger A H Adan
Journal:  BMC Neurosci       Date:  2010-08-11       Impact factor: 3.288

3.  Co-transfection of decorin and interleukin-10 modulates pro-fibrotic extracellular matrix gene expression in human tenocyte culture.

Authors:  Sunny A Abbah; Dilip Thomas; Shane Browne; Timothy O'Brien; Abhay Pandit; Dimitrios I Zeugolis
Journal:  Sci Rep       Date:  2016-02-10       Impact factor: 4.379

4.  Sphingosine-1-phosphate receptor 3 in the medial prefrontal cortex promotes stress resilience by reducing inflammatory processes.

Authors:  Brian F Corbett; Sandra Luz; Jay Arner; Jiah Pearson-Leary; Abhishek Sengupta; Deanne Taylor; Philip Gehrman; Richard Ross; Seema Bhatnagar
Journal:  Nat Commun       Date:  2019-07-17       Impact factor: 14.919

Review 5.  Neuropeptides as targets for the development of anticonvulsant drugs.

Authors:  Elke Clynen; Ann Swijsen; Marjolein Raijmakers; Govert Hoogland; Jean-Michel Rigo
Journal:  Mol Neurobiol       Date:  2014-04-06       Impact factor: 5.590

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.